Polyrizon Ltd. announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma, demonstrated targeted deposition in the nasal vestibule.
The nasal vestibule is identified as the key anatomical site for early allergen contact, reinforcing PL-14's potential as a barrier-forming treatment for allergic rhinitis. The study, led by Professor Fabio Sonvico, utilized a validated silicone-based human nasal cast and fluorescein-labeled imaging.
Results revealed that the PL-14 formulation achieved over 60% deposition in the nasal vestibule, which is critical for effectively blocking allergen contact with the nasal mucosa. This supports the product's mechanism of action as a physical barrier designed to capture and contain environmental allergens. The global allergen blocker market was valued at USD 0.14 billion in 2024 and is expected to reach USD 0.21 billion by 2033.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.